Synmosa Financial Statements From 2010 to 2024
| 4114 Stock | TWD 34.80 0.10 0.29% |
Check Synmosa Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Synmosa Biopharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . Synmosa financial statements analysis is a perfect complement when working with Synmosa Biopharma Valuation or Volatility modules.
Synmosa |
Synmosa Biopharma Company Current Valuation Analysis
Synmosa Biopharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Synmosa Biopharma Current Valuation | 17.93 B |
Most of Synmosa Biopharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Synmosa Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Synmosa Biopharma has a Current Valuation of 17.93 B. This is 24.86% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The current valuation for all Taiwan stocks is 7.88% lower than that of the firm.
Synmosa Biopharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Synmosa Biopharma's current stock value. Our valuation model uses many indicators to compare Synmosa Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Synmosa Biopharma competition to find correlations between indicators driving Synmosa Biopharma's intrinsic value. More Info.Synmosa Biopharma is rated fourth in return on equity category among its peers. It also is rated fourth in return on asset category among its peers reporting about 0.25 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Synmosa Biopharma is roughly 4.01 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Synmosa Biopharma's earnings, one of the primary drivers of an investment's value.About Synmosa Biopharma Financial Statements
Synmosa Biopharma investors use historical fundamental indicators, such as Synmosa Biopharma's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Synmosa Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand name in Taiwan. The company was incorporated in 1980 and is based in Taipei, Taiwan. SYNMOSA BIOPHARMA operates under Drug ManufacturersSpecialty Generic classification in Taiwan and is traded on Taiwan OTC Exchange.
Pair Trading with Synmosa Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Synmosa Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Synmosa Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Synmosa Stock
Moving against Synmosa Stock
| 0.86 | 2610 | China Airlines | PairCorr |
| 0.84 | 2345 | Accton Technology Corp | PairCorr |
| 0.67 | 3533 | Lotes | PairCorr |
| 0.67 | 2360 | Chroma ATE | PairCorr |
| 0.62 | 4123 | Center Laboratories | PairCorr |
The ability to find closely correlated positions to Synmosa Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Synmosa Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Synmosa Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Synmosa Biopharma to buy it.
The correlation of Synmosa Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Synmosa Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Synmosa Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Synmosa Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Synmosa Stock Analysis
When running Synmosa Biopharma's price analysis, check to measure Synmosa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synmosa Biopharma is operating at the current time. Most of Synmosa Biopharma's value examination focuses on studying past and present price action to predict the probability of Synmosa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synmosa Biopharma's price. Additionally, you may evaluate how the addition of Synmosa Biopharma to your portfolios can decrease your overall portfolio volatility.